Author of

• 31105

  +

  P2.06 - Mesothelioma (ID 170)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Mesothelioma
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31124

    +

    P2.06-19 - A Meta-Analysis of Mesothelin, Osteopontin, and Fibulin-3 as Biomarkers of Malignant Pleural Mesothelioma (Now Available) (ID 1729)

    10:15 - 18:15  |  Author(s): Christina Nicole Gillezeau
    • Abstract
    • Slides

    Background
    

    Malignant Pleural Mesothelioma (MPM) is a rare and aggressive cancer; the use of mesothelin, fibulin-3, and osteopontin as biomarkers has been proposed as a screening tool. The following meta-analysis examines average levels of these biomarkers in blood and pleura in comparison to several control groups.

    Method
    

    A PubMed search was conducted for studies that measured the levels of mesothelin, osteopontin, and fibulin-3 in patients with MPM compared to several control groups (other malignancies, benign lung disease, or healthy participants).

    Result
    

    Thirty two studies with 28 distinct datasets were identified as reporting mesothelin levels. Statistically significant mean differences (MD) were observed between mesothelin in the blood of MPM patients and each of the control groups. The overall MD (95% confidence interval) between MPM and non-MPM controls was 3.88 (2.73-5.05) nM/L (nMPM=455). Statistically significant MDs in pleural levels of mesothelin were also seen between MPM patients and non-MPM cancers and benign lung diseases. The overall MD (95%CI) was 31.45 (23.63-39.27) nM/L (nMPM=571). Twelve articles with 10 distinct datasets reported the mean level of osteopontin in MPM cases and controls. Statistically significant MDs in blood levels of osteopontin were seen between MPM patients and benign lung diseases or healthy controls (overall MD (95% CI) 103.75 (54.77-152.72) ng/mL (nMPM=504)), but not with other cancers. Studies on pleural levels of osteopontin were too scarce to conduct a meta-analysis. Nine articles measured fibulin-3 in blood or pleura of MPM patients compared to controls. There was a statistically significant MD in blood levels of fibulin-3 between MPM and each of the control groups. The overall MD (95%CI) was 46.52 (34.04-59.00) ng/mL (nMPM=330). There was also a statistically significant MD in the pleural levels of fibulin-3 between MPM and the cancer and benign lung disease groups. The overall MD (95% CI) was 385.35 (287.98-482.73)ng/mL (nMPM=137).

    Conclusion
    

    This meta-analysis supports the concept that mesothelin and fibulin-3 in control groups are significantly lower than in MPM, and thus they might be useful as screening biomarkers. Further studies are necessary to better assess the value of these promising biomarkers.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.